'Unfair' to accuse hospitals of overpricing remdesivir -- PHA | Inquirer News
Close  

‘Unfair’ to accuse hospitals of overpricing remdesivir — PHA

/ 10:48 AM July 16, 2021
remdesivir

(FILE) This picture shows a vial of Remdesivir at Movianto premises, as parcels of drugs are being sent to India, in Aalst, on April 30, 2021. – Belgium will help India, where the situation in the ongoing pandemic is very severe, with 9000 doses of the antiviral drug Remdesivir. The pharmaceuticals have to be packed in special cases before they leave on a flight tonight. (Photo by DIRK WAEM / various sources / AFP)

MANILA, Philippines — The Philippine Hospital Association (PHA) on Friday said it is “unfair” to accuse hospitals of overpricing the antiviral drug remdesivir used in the treatment of COVID-19 patients, saying hospitals are only selling the drug based on the price set by distributors.

PHA president Dr. Jaime Almora said some hospitals are selling the drug at P25,000 because of its expensive price from the distributors, even as the Department of Health (DOH) said the drug should be sold cheaper.

ADVERTISEMENT

“Naglabas ang DOH ng presyo ng remdesivir na P5,000. ‘Yung mga hospitals naman, especially sa private hospitals, ang binibili nila P25,000 o kaya a little bit less, let’s say P23,000, P24,000, so binebenta ng P25,000,” Almora told ABS-CBN’s Teleradyo.

(The DOH said the price of the remdesivir should be P5,000. Hospitals, especially private hospitals, buy the drug at P25,000, or let’s say a little bit less at P23,000 or P24,000, so they sell it at P25,000.)

FEATURED STORIES

“Dahil sa pronouncement ng DOH na P5,000 ang remdesivir, lumalabas tuloy na nag-ooverprice ang hospital. Napakasakit po nyan. Kasalanan ng DOH ‘yan,” he said.

(Because of the pronouncement of the DOH that remdesivir costs P5,000, it appears that hospitals are overpricing. It hurts to hear that. It is the fault of the DOH.)

Almora also lamented that people believe that hospitals are overpricing the drug for COVID-19 patients.

“Very unfair ‘yung ginagawa ng DOH. Pinapalabas niya tuloy na ang mga hospital ay masasama, naniniwala naman ang mga tao na overpricing ‘yun. Eh ‘yun ang bigay ng distributor eh,” he further said.

(The DOH is very unfair. They made us look that hospitals are at fault and people believed that we were overpricing the drug. But that was the price given by the distributor.)

Almora noted that distributors may also be jacking up the price of remdesivir due to its limited supply. He added that hospitals, in turn, need to set a higher price for the drug in order to make a profit and upgrade its services and equipment.

RELATED STORIES

ADVERTISEMENT

Duque says remdesivir purchase not irregular, welcomes probe should there be one

DOH, DTI urged to regulate prices of COVID-19 therapeutic drugs

/MUF

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

For more news about the novel coronavirus click here.
What you need to know about Coronavirus.
For more information on COVID-19, call the DOH Hotline: (02) 86517800 local 1149/1150.

The Inquirer Foundation supports our healthcare frontliners and is still accepting cash donations to be deposited at Banco de Oro (BDO) current account #007960018860 or donate through PayMaya using this link .

Read Next
Don't miss out on the latest news and information.

Subscribe to INQUIRER PLUS to get access to The Philippine Daily Inquirer & other 70+ titles, share up to 5 gadgets, listen to the news, download as early as 4am & share articles on social media. Call 896 6000.

TAGS: coronavirus Philippines, COVID-19, Department of Health, Jaime Almora, Philippine Hospital Association, remdesivir
For feedback, complaints, or inquiries, contact us.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and
acknowledge that I have read the Privacy Policy.



© Copyright 1997-2021 INQUIRER.net | All Rights Reserved

We use cookies to ensure you get the best experience on our website. By continuing, you are agreeing to our use of cookies. To find out more, please click this link.